Suzhou Zelgen Biopharmaceuticals (SHA:688266) signed a 15-year agreement granting Ares Trading, Merck's Swiss subsidiary, exclusive marketing rights in China for the company's self-developed recombinant human thyroid stimulating hormone (rhTSH) injection.
Under the deal, Zelgen Biopharmaceuticals will receive up to 250 million yuan, with 50 million yuan upfront and 200 million yuan upon first indication approval, according to a Friday filing with the Shanghai bourse.
Ares Trading will earn a percentage of net sales as a service fee.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。